Pet owners increasingly filing claims for lymphoma treatment

As cancers become more and more treatable among the family's pets, claims made for cancer treatment from pet insurance companies are going up, according to an article in Seattle PI.

The article notes that while claims for cancer such as melanoma, carcinomas, mast cell tumors and unspecified masses have gone up considerably over last year, one cancer's costs remain highest per incident: Lymphomas.

According to insurer Petplan, although claims for lymphoma treatments (which can range from radiotherapy to chemotherapy to bone marrow transplantations) are only up 40% from the previous year (compared to melanomas, the claims of which are up 837% over last year), these have the highest per-policy cost, averaging about $2,700, with the highest cost topping $18,000.

This does not mean lymphoma incidence is up, rather it means that more pet owners are insuring their animals against cancerous conditions. Lymphoma remains the most commonly diagnosed cancer in canines, and among the most frequently claimed-for health condition among pets.

Source: Seattle PI

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap